Evidence map›Paper›PMID 26188212›Full record

Trial reportEuropean heart journal2015

Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis.

Taufiq Salahuddin, Balaji Natarajan, Martin P Playford, Aditya A Joshi, Heather Teague, Youssef Masmoudi, Mariana Selwaness, Marcus Y Chen, David A Bluemke, Nehal N Mehta

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01778569 (Human Translational Studies of Inflammation and Cardiometabolic Diseases), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01778569 completednot on this map

Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative

TypeobservationalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2013Enrolled386ConditionsMetabolic Disease, Cardiovascular Disease, Inflammation, Psoriasis
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Observational
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Taufiq SalahuddinCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA.
Balaji NatarajanCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA.
Martin P PlayfordCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA.
Aditya A JoshiCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA.
Heather TeagueCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA.
Youssef MasmoudiCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA.
Mariana SelwanessNational Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA.
Marcus Y ChenCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA.
David A BluemkeNational Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA.
Nehal N MehtaCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, CRC, Room 5-5140, Bethesda, MD 20892, USA nehal.mehta@nih.gov.
National Institutes of Health · USNational Heart Lung and Blood Institute · US

Funding

Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic disease (PACI) InitiativeZIAHL006193 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SACK, MICHAEL · 2014 to 2023
$25.0M
Molecular Biomedical Imaging Laboratory (NIBIB)ZIAEB000072 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI BLUEMKE, DAVID · 2010 to 2017
$5.0M
Molecular Biomedical Imaging Laboratory (CC)ZIACL090019 · CLC · CLINICAL CENTER · PI JONES, ELIZABETH C. · 2010 to 2017
$0k
Howard Hughes Medical InstituteIntramural NIH HHSNHLBI NIH HHS HL006193-01
6 · The paper itself

Abstract

aimsCholesterol efflux capacity (CEC) was recently shown to predict future cardiovascular (CV) events. Psoriasis both increases CV risk and impairs CEC. However, whether having poor CEC is associated with coronary plaque burden is currently unknown. We aimed to assess the cross-sectional relationship between coronary plaque burden assessed by quantitative coronary computed tomography angiography (CCTA) with CEC in a well-phenotyped psoriasis cohort. METHODS AND

resultsTotal burden and non-calcified burden (NCB) plaque indices were assessed in 101 consecutive psoriasis patients using quantitative software. Cholesterol efflux capacity was quantified using a cell-based ex vivo assay measuring the ability of apoB-depleted plasma to mobilize cholesterol from lipid-loaded macrophages. Cholesterol efflux capacity was inversely correlated with NCB (unadjusted β-coefficient -0.33; P < 0.001), and this relationship persisted after adjustment for CV risk factors (β -0.24; P < 0.001), HDL-C levels (β -0.22; P < 0.001), and apoA1 levels (β -0.19; P < 0.001). Finally, we observed a significant gender interaction (P < 0.001) whereby women with low CEC had higher NCB compared to men with low CEC.

conclusionsWe show that CEC is inversely associated with prevalent coronary plaque burden measured by quantitative CCTA. Low CEC may therefore be an important biomarker for subclinical coronary atherosclerosis in psoriasis. CLINICALTRIALSGOV: NCT01778569.

Indexed as

BiomarkersCholesterolCoronary Artery DiseaseFemaleHumansMaleMiddle AgedPlaque, AtheroscleroticProspective StudiesPsoriasisSex CharacteristicsTomography, X-Ray ComputedVascular CalcificationBiomarkersCholesterolCholesterol efflux capacity (CEC)Coronary plaque burdenHDL effluxInflammatory atherogenesisLipidsNon-calcified plaque burdenPsoriasisQuantitative coronary computed tomography angiography (CCTA)

Identifiers

PMID26188212
PMCPMC4604260
OpenAlexW1947718272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.